From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the ...

Paul Hudson [People] delegate AI to CDOs, and it's the biggest mistake you can make. At last year’s World Economic Forum gathering in Davos, Paul Hudson, CEO of French pharma giant Sanofi, made the ...

Paul Hudson Well, as [indiscernible] would have said the answers in the question, OCREVUS had a 24% response rate in PPMS in a pooled data analysis. I think there's lots of efficacy left on the table.

Sanofi CEO Paul Hudson speaks during the Competing In The Global Marketplace: Strategies for Growth panel, at the Fortune Global Forum on Nov. 11, 2024 in New York City.